Pro-Pharmaceuticals, Inc.

Pro-Pharmaceuticals preliminary data shows partial tumor response in stage 1 colon cancer trial

Published in Physician Law Weekly, May 3rd, 2006

Pro-Pharmaceuticals, Inc. (PRW) announced that preliminary data shows an objective partial tumor response from a patient in stage 1 of a Simon's 2-stage designed phase II trial for third- and fourth-line treatment of colorectal cancer, according to response evaluation criteria in solid tumors (RECIST) guidelines.

RECIST defines an objective response as a patient having a complete or partial response, with a partial response being at least a 50% reduction in total tumor size. Based on this preliminary data, the company will not enroll patients in stage 2 and expects to begin dosing patients in a Europe-based phase III trial for the second line treatment of colorectal...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Physician Law Weekly

Source: Physician Law Weekly (2006-05-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry